168 related articles for article (PubMed ID: 37783879)
1. Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells.
Vollmer J; Ecker J; Hielscher T; Valinciute G; Ridinger J; Jamaladdin N; Peterziel H; van Tilburg CM; Oehme I; Witt O; Milde T
J Neurooncol; 2023 Sep; 164(3):617-632. PubMed ID: 37783879
[TBL] [Abstract][Full Text] [Related]
2. Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.
Zeuner S; Vollmer J; Sigaud R; Oppermann S; Peterziel H; ElHarouni D; Oehme I; Witt O; Milde T; Ecker J
J Neurooncol; 2024 Jan; 166(1):99-112. PubMed ID: 38184819
[TBL] [Abstract][Full Text] [Related]
3. Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells.
Valinciute G; Ecker J; Selt F; Hielscher T; Sigaud R; Ridinger J; Thatikonda V; Gatzweiler C; Robinson S; Talbot J; Bernardi F; Picard D; Blattner-Johnson M; Schmid S; Jones DT; van Tilburg CM; Capper D; Kool M; Remke M; Oehme I; Pfister SM; Roussel MF; Ayrault O; Witt O; Milde T
J Neurooncol; 2023 May; 163(1):143-158. PubMed ID: 37183219
[TBL] [Abstract][Full Text] [Related]
4. Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma.
Ecker J; Thatikonda V; Sigismondo G; Selt F; Valinciute G; Oehme I; Müller C; Buhl JL; Ridinger J; Usta D; Qin N; van Tilburg CM; Herold-Mende C; Remke M; Sahm F; Westermann F; Kool M; Wechsler-Reya RJ; Chavez L; Krijgsveld J; Jäger N; Pfister SM; Witt O; Milde T
Neuro Oncol; 2021 Feb; 23(2):226-239. PubMed ID: 32822486
[TBL] [Abstract][Full Text] [Related]
5. Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.
Ecker J; Oehme I; Mazitschek R; Korshunov A; Kool M; Hielscher T; Kiss J; Selt F; Konrad C; Lodrini M; Deubzer HE; von Deimling A; Kulozik AE; Pfister SM; Witt O; Milde T
Acta Neuropathol Commun; 2015 Apr; 3():22. PubMed ID: 25853389
[TBL] [Abstract][Full Text] [Related]
6. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V; Theruvath J; Pauck D; Picard D; Qin N; Blümel L; Maue M; Bartl J; Ahmadov U; Langini M; Meyer FD; Cole A; Cruz-Cruz J; Graef CM; Wölfl M; Milde T; Witt O; Erdreich-Epstein A; Leprivier G; Kahlert U; Stefanski A; Stühler K; Keir ST; Bigner DD; Hauer J; Beez T; Knobbe-Thomsen CB; Fischer U; Felsberg J; Hansen FK; Vibhakar R; Venkatraman S; Cheshier SH; Reifenberger G; Borkhardt A; Kurz T; Remke M; Mitra S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639156
[TBL] [Abstract][Full Text] [Related]
7. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
8. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
[TBL] [Abstract][Full Text] [Related]
9. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
Milde T; Lodrini M; Savelyeva L; Korshunov A; Kool M; Brueckner LM; Antunes AS; Oehme I; Pekrun A; Pfister SM; Kulozik AE; Witt O; Deubzer HE
J Neurooncol; 2012 Dec; 110(3):335-48. PubMed ID: 23054560
[TBL] [Abstract][Full Text] [Related]
10. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
[TBL] [Abstract][Full Text] [Related]
11. HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?
Shofuda T; Kanemura Y
Neuro Oncol; 2021 Feb; 23(2):173-174. PubMed ID: 33394043
[No Abstract] [Full Text] [Related]
12. A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.
Pak E; MacKenzie EL; Zhao X; Pazyra-Murphy MF; Park PMC; Wu L; Shaw DL; Addleson EC; Cayer SS; Lopez BG; Agar NYR; Rubin LL; Qi J; Merk DJ; Segal RA
Neuro Oncol; 2019 Sep; 21(9):1150-1163. PubMed ID: 31111916
[TBL] [Abstract][Full Text] [Related]
13. Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma.
Gwynne WD; Suk Y; Custers S; Mikolajewicz N; Chan JK; Zador Z; Chafe SC; Zhai K; Escudero L; Zhang C; Zaslaver O; Chokshi C; Shaikh MV; Bakhshinyan D; Burns I; Chaudhry I; Nachmani O; Mobilio D; Maich WT; Mero P; Brown KR; Quaile AT; Venugopal C; Moffat J; Montenegro-Burke JR; Singh SK
Cancer Cell; 2022 Dec; 40(12):1488-1502.e7. PubMed ID: 36368321
[TBL] [Abstract][Full Text] [Related]
14. EYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression.
Wolin AR; Vincent MY; Hotz T; Purdy SC; Rosenbaum SR; Hughes CJ; Hsu JY; Oliphant MUJ; Armstrong B; Wessells V; Varella-Garcia M; Galbraith MD; Pierce A; Wang D; Venkataraman S; Danis E; Veo B; Serkova N; Espinosa JM; Gustafson DL; Vibhakar R; Ford HL
Neuro Oncol; 2023 Dec; 25(12):2287-2301. PubMed ID: 37486991
[TBL] [Abstract][Full Text] [Related]
15. HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.
Pei Y; Liu KW; Wang J; Garancher A; Tao R; Esparza LA; Maier DL; Udaka YT; Murad N; Morrissy S; Seker-Cin H; Brabetz S; Qi L; Kogiso M; Schubert S; Olson JM; Cho YJ; Li XN; Crawford JR; Levy ML; Kool M; Pfister SM; Taylor MD; Wechsler-Reya RJ
Cancer Cell; 2016 Mar; 29(3):311-323. PubMed ID: 26977882
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid treatment response in vitro is determined by TP53 status in medulloblastoma.
Mascaro-Cordeiro B; Oliveira ID; Tesser-Gamba F; Pavon LF; Saba-Silva N; Cavalheiro S; Dastoli P; Toledo SRC
Childs Nerv Syst; 2018 Aug; 34(8):1497-1509. PubMed ID: 29785653
[TBL] [Abstract][Full Text] [Related]
17. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
18. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
[TBL] [Abstract][Full Text] [Related]
20. Marinopyrrole derivative MP1 as a novel anti-cancer agent in group 3 MYC-amplified Medulloblastoma.
Coulter DW; Chhonker YS; Kumar D; Kesherwani V; Aldhafiri WN; McIntyre EM; Alexander G; Ray S; Joshi SS; Li R; Murry DJ; Chaturvedi NK
J Exp Clin Cancer Res; 2024 Jan; 43(1):18. PubMed ID: 38200580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
